The landmark SUSTAIN clinical trial series evaluated semaglutide in thousands of patients with type 2 diabetes, providing data on various metabolic parameters including lipid profiles
[1] [4] In animal studies, tirzepatide was associated with thyroid C-cell tumours, though the relevance to humans is unknown and this is not listed as an adverse reaction in the UK SmPC
Ozempic and Wegovy are once-weekly injectable weight loss medications now approved by the FDA for the long-term treatment of diabetes and obesity
Module for $35
By Wissam Ghusn, MD, Alan De la Rosa, MD, Daniel Sacoto, MD, Lizeth Cifuentes, MD, Alejandro Campos, MD, Fauzi Feris, MD, Maria Daniela Hurtado, MD, PhD, and Andres Acosta, MD, PhD